ALKERMES | ALKS - Capitale Sociale E Riserve





Capitale Sociale E Riserve Cambiamento Data
AbbVie USD -6.66B 3.39B 2026-03
Acadia Pharmaceuticals USD 1.25B 20.68M 2026-03
ALKERMES USD 1.75B 67.76M 2026-03
Amgen USD 9.19B 532M 2026-03
Biogen USD 18.65B 394.9M 2026-03
BioMarin Pharmaceutical USD 6.21B 125.11M 2026-03
Bristol-Myers Squibb USD 20.07B 1.6B 2026-03
Coherus Biosciences USD 61.01M 26.76M 2025-12
Eli Lilly USD 31.2B 4.66B 2026-03
Gilead Sciences USD 23.52B 897M 2026-03
Heron Therapeutics USD 9.14M 4.15M 2026-03
Ionis Pharmaceuticals USD 491.41M 2.32M 2026-03
J&J USD 81.19B 358M 2026-03
Malin Corporation EUR 193.2M 75M 2024-12
Merck USD 45.88B 6.73B 2026-03
Minerva Neurosciences USD -140.75M 106.17M 2025-12
Nektar Therapeutics USD 89.83M 4.75M 2025-12
Neurocrine Biosciences USD 3.41B 154.3M 2026-03
Otsuka Holdings JPY 3.11T 74.63B 2026-03
Ovoca Bio EUR 1.26M 7.41M 2025-06
Pfizer USD 90.1B 3.63B 2026-03
Regeneron Pharmaceuticals USD 31.42B 166.7M 2026-03
Vertex Pharmaceuticals USD 19.36B 696.1M 2026-03